Screener
ArriVent BioPharma, Inc. AVBP Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeNet.
The source filing: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-058650
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| General and administrative | 8,494 | 5,483 |
| Total operating expenses | 46,111 | 66,772 |
| Operating loss | (46,111) | (66,772) |
| Interest and investment income | 2,791 | 2,385 |
| Net loss | (43,320) | (64,387) |
| Unrealized gain (loss) on marketable securities | (284) | 194 |
| Total other comprehensive gain (loss) | (284) | 194 |
| Total comprehensive loss | $(43,604) | $(64,193) |
Item 1. Condensed Financial Statements (Unaudited):
FAQ
- What is ArriVent BioPharma, Inc.'s interest income?
- ArriVent BioPharma, Inc. (AVBP) reported interest income of $2.79M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s interest income changed year-over-year?
- ArriVent BioPharma, Inc.'s interest income increased by 17.0% year-over-year, from $2.39M to $2.79M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s interest income?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s interest income has grown at a 46.1% compound annual growth rate (CAGR), from $5.26M to $11.23M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about ArriVent BioPharma, Inc.'s interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude